Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.
Journal Information
Full Title: Br J Cancer
Abbreviation: Br J Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests HS: Consultant/advisory board: Hutchison, Bayer, ITM, AAA. Lecture Honoraria; Novartis, Ipsen, Bayer, SAM Nordic, Pierre Fabre. ML: Unrestricted research grant from Scandion Oncology A/S."
Funding Disclosure
Evidence found in paper:
"Funding The study received a research grant from Novartis."
Protocol Registration
Evidence found in paper:
"Clinical trial registration ClinicalTrials.gov (NTC02248012)."
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025